AMENDMENT TO THE CLINICAL STUDY AGREEMENTThe Clinical Study Agreement • October 18th, 2020
Second Amendment (the “Amendment”) effective upon execution by all parties to that certain Clinical Study Agreement (the “Agreement”), effective March 27, 2015 and amended June 19, 2015, between University Hospital Plzen, Alej Svobody 80, Plzen 304 60 (“Institution”) and AbbVie s.r.o., Metronom Business Center,Bucharova 2817/13 158 00 Praha 5 - Nové Butovice,Czech Republic (“AbbVie”) for Services relating to the Protocol No. M11-290 entitled “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis”.
FIRST SUPPLEMENT TO THE CLINICAL STUDY AGREEMENTThe Clinical Study Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Supplement to the Clinical Study Agreement (the “First Supplement”) is made on the last day of signature (the “Effective Date”) and is made by and between Cancer Insight, LLC (“Cancer Insight”) and BriaCell Therapeutics Corporation (“BriaCell”) (each a “Party” and collectively the “Parties”).
